Les résultats et les conclusions des travaux menés par l’écosystème Experts Recherche Lymphome sont publiés dans des journaux médicaux de premier plan.
    Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma
  
    
      
    
    
      
  
  
                   
        Blood Adv. 2018 Apr 10;2(7):807-816. doi: 10.1182/bloodadvances.2017015164.
              
    
    How I manage patients with relapsed/refractory diffuse large B cell lymphoma
  
    
      
    
    
      
  
  
                   
        Br J Haematol. 2018 May 29. doi: 10.1111/bjh.15412.
              
    
    Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
  
    
      
    
    
      
  
  
                   
        Haematologica 2018 May;103(5):840-848. doi: 10.3324/haematol.2017.180554
              
    
    Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil.
  
    
      
    
    
      
  
  
                   
        Blood. 2018 May 2. pii: blood-2018-02-811174. doi: 10.1182/blood-2018-02-811174.
              
    
    HLA class I and II diversity contributes to the etiologic heterogeneity of non-Hodgkin lymphoma subtypes
  
    
      
    
    
      
  
  
                   
        Cancer Res. 2018 May 7. pii: canres.2900.2017. doi: 10.1158/0008-5472.CAN-17-2900.
              
    
    NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment.
  
    
      
    
    
      
  
  
                   
        Oncoimmunology. 2017 Dec 20;7(4):e1409322. doi: 10.1080/2162402X.2017.1409322. eCollection 2018.
              
    
    2018_LYSA_Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: a series from LYSA centers.
  
    
      
    
    
      
  
  
                   
        Am J Hematol. 2018 Jun 8. doi: 10.1002/ajh.25154.
              
    
    Progression-Free Survival at 24 Months (PFS24) and Subsequent Outcome For Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled On Randomized Clinical Trials.
  
    
      
    
    
      
  
  
                   
        Ann. Oncol. 2018 Jun 12. doi: 10.1093/annonc/mdy203.
              
    
    Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study.
  
    
      
    
    
      
  
  
                   
        Br J Haematol. 2018 Aug 16. doi: 10.1111/bjh.15513
              
    
    An open-label, phase Ib study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.
  
    
      
    
    
      
  
  
                   
        Blood. 2018 Aug 1. pii: blood-2018-05-853499. doi: 10.1182/blood-2018-05-853499.
              
    
    A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first line treatment of older patients with mantle cell lymphoma
  
    
      
    
    
      
  
  
                   
        Haematologica 2018 Aug 31. pii: haematol.2018.191429. doi: 10.3324/haematol.2018.191429
              
    
    How I manage patients with relapsed/refractory diffuse large B cell lymphoma.
  
    
      
    
    
      
  
  
                   
        Br J Haematol 2018 Sep;182(5):633-643. doi: 10.1111/bjh.15412
              
    
    Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
  
    
      
    
    
      
  
  
                   
        N Engl J Med. 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104
              
    
    Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.
  
    
      
    
    
      
  
  
                   
        Lancet Haematol. 2018 Sep;5(9):e403-e410. doi: 10.1016/S2352-3026(18)30131-5
              
    
    Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma
  
    
      
    
    
      
  
  
                   
        Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1705-1709. doi: 10.1007/s00259-018-4020-5
              
    
    
          Lysa
      
    2020_LYSA_Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers
  
    
      
    
    
      
  
  
                   
        Bone Marrow Transplant. 2020 Jan 17. doi: 10.1038/s41409-020-0783-y
                  En savoir plus 
              
    
    
          Lysa
      
    2020_LYSA_A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features
  
    
      
    
    
      
  
  
                   
        Clin Cancer Res. 2020 Mar 2. doi: 10.1158/1078-0432.CCR-19-3741. 
                  En savoir plus 
              
    
    
          Lysa
      
    2020_LYSA_Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study
  
    
      
    
    
      
  
  
                   
        Lancet Haematol. 2020 Feb;7(2):e112-e121. doi: 10.1016/S2352-3026(19)30210-8
                  En savoir plus 
              
    
    
          Lysa
      
    2020_LYSA_Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma
  
    
      
    
    
      
  
  
                   
        Radiology. 2020 Apr 14:192056. doi: 10.1148/radiol.2020192056.
                  En savoir plus 
              
    
    Locus suicide recombination actively occurs on the functionally rearranged IgH allele in B-cells from inflamed human lymphoid tissues.
  
    
      
    
    
      
  
  
                   
        PLoS Genet. 2019 Jun 14
                  En savoir plus 
              
    
    
          Calym
      
    Mesangial Deposition Can Strongly Involve Innate-Like IgA Molecules Lacking Affinity Maturation
  
    
      
    
    
      
  
  
                   
        Am Soc Nephrol. 2019 Jul
                  En savoir plus 
              
    
    
          Calym
      
    An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence
  
    
      
    
    
      
  
  
                   
        Nat Commun. 2019 Nov 6
                  En savoir plus 
              
    
    
          Calym
      
    Pb Alpha-Radioimmunotherapy targeting CD38 in Multiple Myeloma: a preclinical study
  
    
      
    
    
      
  
  
                   
        Nucl Med. 2019 Dec 20. pii: jnumed.119.239491. doi: 10.2967/jnumed.119.239491.
                  En savoir plus 
              
    
    
          Calym
      
    Immunoglobulin variable domain high-throughput sequencing reveals specific novel mutational patterns in POEMS syndrome., »/
  
    
      
    
    
      
  
  
                
        
      
        Blood.  2020 PMID: 32243509 DOI: 10.1182/blood.2019004197 
                  En savoir plus